Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
dc.contributor.author | Eskiler, Gamze Güney | |
dc.contributor.buuauthor | Çeçener, Gülşah | |
dc.contributor.buuauthor | Egeli, Ünal | |
dc.contributor.buuauthor | Tunca, Berrin | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-1619-6680 | tr_TR |
dc.contributor.orcid | 0000-0001-7904-883X | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | tr_TR |
dc.contributor.researcherid | ABI-6078-2020 | tr_TR |
dc.contributor.researcherid | AAH-1420-2021 | tr_TR |
dc.date.accessioned | 2024-01-12T06:08:00Z | |
dc.date.available | 2024-01-12T06:08:00Z | |
dc.date.issued | 2018-09 | |
dc.description | Bu çalışma, 14-15 Eylül, 2018 tarihlerinde Paris[Fransa]’da düzenlenen Conference on Molecular Analysis for Personalised Therapy (MAP) Kongresi‘nde bildiri olarak sunulmuştur. | tr_TR |
dc.identifier.citation | Eskiler, G. G. vd. (2018). ''Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer''. Annals of Oncology, 29(Supplement 6). | en_US |
dc.identifier.doi | https://doi.org/10.1093/annonc/mdy314.008 | |
dc.identifier.eissn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issue | Supplement 6 | en_US |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0923753419323026 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/38977 | |
dc.identifier.volume | 29 | tr_TR |
dc.identifier.wos | 000458248200063 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | CPCIS | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.bap | BUAP(T)-2015/1 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | Annals of Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject.wos | Oncology | en_US |
dc.title | Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q1 (Oncology) | en_US |